{
  "@context": "http://id.who.int/icd/contexts/contextForLinearizationEntity.json",
  "@id": "http://id.who.int/icd/release/11/2024-01/mms/674464254",
  "parent": [
    "http://id.who.int/icd/release/11/2024-01/mms/405257730"
  ],
  "browserUrl": "https://icd.who.int/browse/2024-01/mms/en#674464254",
  "code": "4A85.00",
  "source": "http://id.who.int/icd/entity/674464254",
  "classKind": "category",
  "postcoordinationScale": [
    {
      "@id": "http://id.who.int/icd/release/11/2024-01/mms/674464254/postcoordinationScale/associatedWith",
      "axisName": "http://id.who.int/icd/schema/associatedWith",
      "requiredPostcoordination": "false",
      "allowMultipleValues": "AllowAlways",
      "scaleEntity": [
        "http://id.who.int/icd/release/11/2024-01/mms/1583926619",
        "http://id.who.int/icd/release/11/2024-01/mms/1323892810"
      ]
    }
  ],
  "title": {
    "@language": "en",
    "@value": "Drug-induced liver hypersensitivity disease"
  },
  "definition": {
    "@language": "en",
    "@value": "Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine."
  },
  "indexTerm": [
    {
      "label": {
        "@language": "en",
        "@value": "Drug-induced liver hypersensitivity disease"
      }
    },
    {
      "label": {
        "@language": "en",
        "@value": "medicament-induced liver hypersensitivity disease"
      }
    },
    {
      "label": {
        "@language": "en",
        "@value": "Immune-mediated DILI - [drug-induced liver injury]"
      }
    }
  ]
}